“What we found was the [progression-free survival] value was improved in the subgroup of patients with low [alkaline phosphatase levels],” says Michel Pavic, MD.
Body: In this video, Michel Pavic, MD, discusses the background and findings of the study, “Masitinib plus docetaxel as first-line treatment of metastatic castrate refractory prostate cancer: results from study AB12003,” presented recently at the 2021 American Urological Association Annual Meeting. Pavic is an oncologist and head of the hematology-oncology service at CIUSSS de l’Estrie (CHUS) and a professor of medicine and health sciences at the University of Sherbrooke, Quebec, Canada.
Plant-based diets linked to lower risk of prostate cancer progression and recurrence
March 7th 2023"These findings may directly inform clinical care, such as providing diet recommendations for managing health, and potentially offer other positive health benefits for preventing numerous chronic diseases,” said Bradley Alexander McGregor, MD.
Gene therapy EG-70 shows early promise in BCG-unresponsive NMIBC
February 27th 2023"While the data are still early, EG-70's safety profile and efficacy are well on their way towards establishing a new benchmark for monotherapy treatment of high-risk NMIBC with BCG-unresponsive carcinoma in situ,” said lead study author Gary Steinberg MD.
Real-world study investigates first-line avelumab maintenance for metastatic urothelial carcinoma
February 20th 2023Baseline findings showed that patients treated with first-line platinum-based chemotherapy prior to avelumab maintenance experienced a complete response rate of 13% and a partial response rate of 68% to chemotherapy.
2 Clarke Drive
Cranbury, NJ 08512